SASTASUNDR2024-07-012024-09-30 SASTASUNDR2024-07-012024-09-30 SASTASUNDR2024-07-012024-09-30in-bse-fin:OneOtherRevenueFromOperations01Member SASTASUNDR2024-07-012024-09-30in-bse-fin:FourOtherRevenueFromOperations01Member SASTASUNDR2024-07-012024-09-30in-bse-fin:OneOperatingExpenses01Member SASTASUNDR2024-07-012024-09-30in-bse-fin:FourOperatingExpenses01Member SASTASUNDR2024-09-30 SASTASUNDR2024-07-012024-09-30in-bse-fin:OneReportableSegmentRevenue01Member SASTASUNDR2024-07-012024-09-30in-bse-fin:OneReportableSegmentRevenue02Member SASTASUNDR2024-07-012024-09-30in-bse-fin:FourReportableSegmentRevenue01Member SASTASUNDR2024-07-012024-09-30in-bse-fin:FourReportableSegmentRevenue02Member SASTASUNDR2024-07-012024-09-30in-bse-fin:OneReportableSegmentResults01Member SASTASUNDR2024-07-012024-09-30in-bse-fin:OneReportableSegmentResults02Member SASTASUNDR2024-07-012024-09-30in-bse-fin:FourReportableSegmentResults01Member SASTASUNDR2024-07-012024-09-30in-bse-fin:FourReportableSegmentResults02Member SASTASUNDR2024-07-012024-09-30in-bse-fin:OneReportableSegmentAssets01Member SASTASUNDR2024-07-012024-09-30in-bse-fin:OneReportableSegmentAssets02Member SASTASUNDR2024-07-012024-09-30in-bse-fin:OneReportableSegmentLiabilities01Member SASTASUNDR2024-09-30in-bse-fin:OneReportableSegmentLiabilities01Member SASTASUNDR2024-09-30 SASTASUNDR2024-07-012024-09-30in-bse-fin:OneReportableSegmentLiabilities02Member SASTASUNDR2024-09-30in-bse-fin:OneReportableSegmentLiabilities02Member SASTASUNDR2024-07-012024-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member SASTASUNDR2024-07-012024-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 533259 SASTASUNDR NOTLISTED Sastasundar Ventures Limited Equity 2024-04-01 2025-03-31 2024-11-14 2024-11-07 INR Lakhs Half yearly 2024-11-14 15:00:00 2024-11-14 17:55:00 true Cash Flow Indirect Not applicable Multi segment 2024-07-01 2024-09-30 Unaudited Consolidated 1938000.00 2774000.00 0.00 0.00 94401000.00 0.00 2626632000.00 8374000.00 1188000.00 2735307000.00 222928000.00 2958235000.00 4586000.00 2347895000.00 111080000.00 116276000.00 574000.00 14529000.00 0.00 0.00 0.00 0.00 202814000.00 2797754000.00 160481000.00 -1896759000.00 -1736278000.00 2497000.00 -231238000.00 -228741000.00 -1507537000.00 0.00 0.00 0.00 -40339000.00 -1547876000.00 -772000.00 -1548648000.00 -1094142000.00 -453734000.00 -1094680000.00 -453968000.00 318105000.00 10 -34.40 -34.40 0.00 0.00 -34.40 -34.40 0.00 0.00 0.00 Notes: 1. The above Unaudited Consolidated Financial Results for the quarter and half year ended September 30, 2024 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on November 14, 2024. The Limited Review for the quarter and half year ended September 30, 2024 has been carried out by the Statutory Auditors, as required under Regulation 33 of SEBI (LODR) Regulation, 2015. 3. Exceptional items represent the gain on following transaction/ event: (a) During the Financial Year 2022-23, subsidiaries of the Company had expensed Rs. 796.45 Lakhs under the heading “Exceptional Item”. Sastasundar Healthbuddy Limited, subsidiary of the Company has now recovered Rs. 100.00 Lakhs against the aforesaid amount which has been booked as income in the Previous Quarter under the heading “exceptional item” (b) The subsidiary of the company, Sastasundar healthbuddy Limited, has liquidated its Investment held in the form of 0.01% Non-Cumulative Compulsory Convertible Preference share and Equity shares in Flipkart Health Limited on 29th October 2024 as per Share Purchase Agreement dated 28th October 2024 and received a consideration of Rs 9,717.00 Lakhs in aggregate. Further, since the actual transaction took place after the reporting period ended September 30, 2024 but prior to the scheduled board meeting date the accounting impact of the resultant loss of Rs 18,895.22 Lakhs has been booked as exceptional items in the standalone financial result for the period ended September 30, 2024. (c) The management of one of the step down subsidiary, Genu Path Labs Limited, has evaluated its business operation and the management is of the opinion that the Property, Plant & Equipment as held by it needs to be impaired. Accordingly the company has accounted for an impairment loss of Rs 72.37 Lakhs and disclosed the same as Exceptional item in the financial results for the half year ended September 30, 2024. 4. Happymate Foods Limited, step down subsidiary of the company had started its operation in fast moving consumer goods in 2018 with an aim to reach the consumer with a premium brand. The company has taken various steps since then to build distribution channel & offline stores, which did not turn out as expected and losses has been incurred. Presently the company is into discussion with business partner on further plans of restructuring its business. 5. The subsidiary of the company, Sastasundar Healthbuddy Limited had received final approval order from National Company Law Tribunal on October 17th 2024 for merger of Retailer Shakti Supply Chain Private Limited a wholly owned subsidiary of Sastasundar Healthbuddy Limited. Upon receipt of such order from National Company Law Tribunal with the appointed date April 01, 2023, the standalone financial results of the subsidiary of the company, Sastasundar Healthbuddy Limited has been prepared after giving effect to such order. Consequently, the consolidated results of the company for the Quarter ended June 30, 2024, Quarter ended September 30, 2023, half year ended September 30, 2023, Financial Year ended March 31, 2024 has been restated accordingly . The following tables summarises the impact on the financials results. 6. Sastasundar Healthtech Private Limited, a step down subsidiary company has been incorprated on July 18, 2024 which has been consolidated in the above results. Multi segment 2024-04-01 2024-09-30 Unaudited Consolidated 3813000.00 3038000.00 0.00 0.00 165405000.00 0.00 5246567000.00 17080000.00 2333000.00 5438236000.00 500427000.00 5938663000.00 10768000.00 4795569000.00 84444000.00 222467000.00 1541000.00 30609000.00 0.00 0.00 0.00 0.00 396351000.00 5541749000.00 396914000.00 -1886759000.00 -1489845000.00 3265000.00 -490251000.00 -486986000.00 -1002859000.00 0.00 0.00 0.00 -130374000.00 -1133233000.00 1835000.00 -1131398000.00 -779034000.00 -354199000.00 -777669000.00 -353729000.00 318105000.00 10 -24.49 -24.49 0.00 0.00 -24.49 -24.49 0.00 0.00 0.00 Other Financial Income 1188000.00 Other Financial Income 2333000.00 Other expenses 202814000.00 Other expenses 396351000.00 250074000.00 721000.00 0.00 245616000.00 0.00 87342000.00 4662454000.00 2242523000.00 7488730000.00 1065569000.00 54532000.00 3659000.00 23893000.00 0.00 653264000.00 5074000.00 0.00 361434000.00 336000.00 390948000.00 2558709000.00 10047439000.00 318105000.00 6568720000.00 8920431000.00 0.00 0.00 33721000.00 518150000.00 0.00 0.00 0.00 0.00 0.00 11268000.00 221323000.00 784462000.00 0.00 55209000.00 176472000.00 110865000.00 342546000.00 10047439000.00 Financial Services 100301000.00 Healthcare Network 2635006000.00 Financial Services 174589000.00 Healthcare Network 5263647000.00 2735307000.00 5438236000.00 0.00 0.00 2735307000.00 5438236000.00 Financial Services 91790000.00 Healthcare Network -2039627000.00 Financial Services 159892000.00 Healthcare Network -2127187000.00 -1947837000.00 -1967295000.00 574000.00 1541000.00 -212133000.00 -478991000.00 -1736278000.00 -1489845000.00 Financial Services 809112000.00 Healthcare Network 8603084000.00 9412196000.00 635243000.00 10047439000.00 Financial Services 52648000.00 Healthcare Network 1061239000.00 1113887000.00 13121000.00 1127008000.00 2. The Group has identified the following segments : Financial Services - consists mainly of financing of loans and investment in shares and securities, financial consultancy, professional fees, wealth management, financial planning, distribution and related services. Healthcare Network - includes activities for pathology, food processing and marketing of healthcare and OTC products through e-commerce portal and diagnostic services which consist of pathological / radiological investigations. (a) Items that will be not reclassified subsequently to profit or loss -724000.00 (a) Items that will be not reclassified subsequently to profit or loss 1874000.00 -724000.00 1874000.00 48000.00 39000.00 0.00 0.00 -772000.00 1835000.00 1541000.00 92378000.00 179813000.00 0.00 30656000.00 0.00 -4170000.00 -194377000.00 0.00 130725000.00 0.00 12466000.00 0.00 30609000.00 0.00 0.00 -4868000.00 -37984000.00 0.00 0.00 3038000.00 93816000.00 0.00 -510843000.00 0.00 -43842000.00 0.00 1902402000.00 0.00 1487652000.00 -2193000.00 0.00 0.00 0.00 17437000.00 0.00 -19630000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -21396000.00 5901000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1461544000.00 1739358000.00 0.00 0.00 0.00 0.00 2982000.00 53818000.00 0.00 185015000.00 0.00 -63296000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2870000.00 0.00 207000.00 0.00 0.00 -3077000.00 -86003000.00 0.00 -86003000.00 336077000.00 250074000.00